Meta-Analysis
Copyright ©The Author(s) 2017.
World J Cardiol. Feb 26, 2017; 9(2): 182-190
Published online Feb 26, 2017. doi: 10.4330/wjc.v9.i2.182
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Comparison of Mantel-Haenszel risk ratio for combined end points of cardiovascular death and hospitalization for heart failure between ivabradine + beta-blocker vs beta-blocker alone. MH RR: Mantel-Haenszel risk ratio; BB: Beta blockers.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Comparison of mean change in heart rates from baseline between ivabradine + beta-blocker vs beta-blocker alone. BB: Beta blockers.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Comparison of mean change in heart rates from baseline between ivabradine + beta-blocker vs beta-blocker alone including only randomized controlled trials. BB: Beta blockers.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Comparison of Mantel-Haenszel risk ratio for all cause mortality between ivabradine + beta-blocker vs beta-blocker alone. BB: Beta blockers.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Comparison of Mantel-Haenszel risk ratio for cardiovascular mortality between ivabradine + beta-blocker vs beta-blocker alone. BB: Beta blockers.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Comparison of Mantel-Haenszel risk ratio for heart failure hospitalization between ivabradine + beta-blocker vs beta-blocker alone. BB: Beta blockers.
Figure 7
Open in New Tab Full Size Figure Download Figure
Figure 7 Comparison of difference in means of 6-min walking distance between ivabradine + beta-blocker vs beta-blocker alone. BB: Beta blockers.
Figure 8
Open in New Tab Full Size Figure Download Figure
Figure 8 Comparison of difference in means of ejection fraction between ivabradine + beta-blocker vs beta-blocker alone. BB: Beta blockers.